LifeMD Appoints Veteran Healthcare Finance Executive Atul Kavthekar as New CFO; Expands Leadership Team
Summary
LifeMD announced the departure of its CFO, Marc Benathen, and the immediate appointment of Atul Kavthekar, a seasoned healthcare finance executive, as his successor. The company also promoted Jessica Friedeman to Chief Business Officer and Chris Pisano to Chief Marketing Officer.
Key Events
-
CFO Departure
Marc Benathen resigned as Chief Financial Officer, effective March 31, 2026, to pursue a new opportunity. He will provide transition services for six to twelve months at a fee of $38,117 per month.
-
New CFO Appointment
Atul Kavthekar was appointed Chief Financial Officer, effective March 16, 2026. He brings nearly three decades of executive leadership and financial expertise spanning provider-side healthcare, retail and specialty pharmacy, and e-commerce.
-
Significant Equity Grant for New CFO
As a material inducement to his employment, Mr. Kavthekar will be granted 675,000 restricted stock units (RSUs), with 337,500 time-based and 337,500 performance-based.
-
Leadership Team Expansion
Jessica Friedeman was promoted to Chief Business Officer and Chris Pisano to Chief Marketing Officer, further strengthening the executive leadership team.
Analysis
This filing details significant leadership changes at LifeMD, occurring shortly after the company disclosed a financial restatement and material weaknesses in its internal controls in its recent 10-K. While the departure of CFO Marc Benathen is a notable event, the immediate appointment of Atul Kavthekar, who brings extensive experience in healthcare, M&A, and building scalable financial infrastructure, is a strong positive signal. His substantial RSU grant (valued at approximately $2.75 million, representing about 1.4% of the company's market cap) aligns his incentives with long-term shareholder value. The additional promotions of Jessica Friedeman and Chris Pisano further strengthen the executive team, indicating a proactive effort to address operational and strategic growth following recent financial challenges. Investors should view these changes as a strategic move to stabilize and enhance the company's financial and operational leadership.
At the time of this filing, LFMD was trading at $4.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $197.2M. The 52-week trading range was $2.56 to $15.84. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.